ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Clinical Use of Anabolics and Hormones
Clinical Use of Anabolics and Hormones
Nandrolone ( Deca Durabolin) Improves Joint Pain in Hypogonadal Men Within 8 Weeks
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 128684" data-attributes="member: 3"><p>Recently presented at a Urology conference Nov 2018 in Miami.</p><p></p><p><strong>Title:<span style="font-size: 15px"> Nandrolone Decanoate Improves Joint Pain in Hypogonadal Men Within 8 Weeks: A Novel Prospective Pilot Study</span></strong></p><p></p><p></p><p><strong>Authors:</strong> Alexander J. Tatem, Jonathan A. Beilan, Jason R. Kovac, Jabez Gondokusumo, Nannan Thirumavalavan, Larry I. Lipshultz</p><p></p><p></p><p><strong>Introduction and Objective</strong></p><p></p><p>5-20% of adult men suffer from hypogonadism (HG). Comorbidities linked with HG, such as diabetes and obesity, are often associated with significant and debilitating joint pain (JP). Nandrolone decanoate (ND) is an FDA approved testosterone derivative for treatment of anemia and muscle-wasting syndrome that has anecdotally been linked to reduced JP. Here we quantify this effect prospectively in a novel pilot study.</p><p></p><p><strong>Methods</strong></p><p></p><p>Hypogonadal men taking injectable testosterone therapy (TTh) presenting to a single andrology clinic between July 2018 and October 2018 were evaluated for the presence of JP. Men who reported significant JP and denied prior ND usage were invited to take part in the study.</p><p></p><p>The Rheumatoid Arthritis Pain Scale (RAPS) is a validated questionnaire initially developed to assess/characterize pain levels in adults with rheumatoid arthritis. It contains 24 statements about JP that patients assign a value ranging from 0 (never) to 6 (always). Pain scores are totaled with higher scores representing worse pain and can then be divided into physiologic, affective, sensory-discriminative, and cognitive components.</p><p></p><p>Men were asked to complete the RAPS questionnaire prior to starting ND. Patient-specific characteristics were recorded, including pain location and pain medication use/dosages. Men subsequently started injectable ND at half the dosage of their current testosterone regimen with all other medications kept constant. After 8 weeks, they filled out the survey again.</p><p></p><p><strong>Results</strong></p><p></p><p>32 eligible patients completed the initial survey and 11 men (34.4%) responded to follow-up requests at the time of this review. Mean duration of therapy was 54 days. All patients reported marked improvements in JP with 4 (36.4%) reporting a decreased need for pain medication. Patients’ total pain scores decreased from an average of 61.7 to 34.5 (p=0.038). Significant improvements in each sub-category were noted (<strong>Table 1</strong>). No adverse events were reported.</p><p></p><p><strong>[ATTACH=full]6240[/ATTACH]</strong></p><p></p><p><strong>Conclusions</strong></p><p></p><p>ND is a promising new adjunctive therapy for hypogonadal men with JP. It reduced pain scores by an average of 44% and decreased pain medication requirements in 36.4% of patients. Reducing pain medication needs is paramount in today’s opioid crisis climate. Further studies are required to better characterize ND’s effects across a larger study population.</p><p><a href="https://www.excelmale.com/forum/threads/all-about-nandrolone.9186/" target="_blank">All About Nandrolone</a></p><p></p><p></p><p><strong>Source of Funding:</strong> This work is supported in part by NIH grant K12 DK0083014, the Multidisciplinary K12 Urologic Research (KURe) Career Development Program (NT is a K12 Scholar).</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 128684, member: 3"] Recently presented at a Urology conference Nov 2018 in Miami. [B]Title:[SIZE=15px] Nandrolone Decanoate Improves Joint Pain in Hypogonadal Men Within 8 Weeks: A Novel Prospective Pilot Study[/SIZE][/B] [B]Authors:[/B] Alexander J. Tatem, Jonathan A. Beilan, Jason R. Kovac, Jabez Gondokusumo, Nannan Thirumavalavan, Larry I. Lipshultz [B]Introduction and Objective[/B] 5-20% of adult men suffer from hypogonadism (HG). Comorbidities linked with HG, such as diabetes and obesity, are often associated with significant and debilitating joint pain (JP). Nandrolone decanoate (ND) is an FDA approved testosterone derivative for treatment of anemia and muscle-wasting syndrome that has anecdotally been linked to reduced JP. Here we quantify this effect prospectively in a novel pilot study. [B]Methods[/B] Hypogonadal men taking injectable testosterone therapy (TTh) presenting to a single andrology clinic between July 2018 and October 2018 were evaluated for the presence of JP. Men who reported significant JP and denied prior ND usage were invited to take part in the study. The Rheumatoid Arthritis Pain Scale (RAPS) is a validated questionnaire initially developed to assess/characterize pain levels in adults with rheumatoid arthritis. It contains 24 statements about JP that patients assign a value ranging from 0 (never) to 6 (always). Pain scores are totaled with higher scores representing worse pain and can then be divided into physiologic, affective, sensory-discriminative, and cognitive components. Men were asked to complete the RAPS questionnaire prior to starting ND. Patient-specific characteristics were recorded, including pain location and pain medication use/dosages. Men subsequently started injectable ND at half the dosage of their current testosterone regimen with all other medications kept constant. After 8 weeks, they filled out the survey again. [B]Results[/B] 32 eligible patients completed the initial survey and 11 men (34.4%) responded to follow-up requests at the time of this review. Mean duration of therapy was 54 days. All patients reported marked improvements in JP with 4 (36.4%) reporting a decreased need for pain medication. Patients’ total pain scores decreased from an average of 61.7 to 34.5 (p=0.038). Significant improvements in each sub-category were noted ([B]Table 1[/B]). No adverse events were reported. [B][ATTACH=full]6240[/ATTACH][/B] [B]Conclusions[/B] ND is a promising new adjunctive therapy for hypogonadal men with JP. It reduced pain scores by an average of 44% and decreased pain medication requirements in 36.4% of patients. Reducing pain medication needs is paramount in today’s opioid crisis climate. Further studies are required to better characterize ND’s effects across a larger study population. [URL="https://www.excelmale.com/forum/threads/all-about-nandrolone.9186/"]All About Nandrolone[/URL] [B]Source of Funding:[/B] This work is supported in part by NIH grant K12 DK0083014, the Multidisciplinary K12 Urologic Research (KURe) Career Development Program (NT is a K12 Scholar). [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Clinical Use of Anabolics and Hormones
Clinical Use of Anabolics and Hormones
Nandrolone ( Deca Durabolin) Improves Joint Pain in Hypogonadal Men Within 8 Weeks
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top